Neil Romberg

Neil Romberg

Auto-generated profile, based on publicly available information

Neil Romberg

Division of Immunology and Allergy, Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2018 in Nature
Verified
Journal Article
Closed access
PDF file
TRTheodore L. Roth
Theodore L. Roth
CPCristina Puig-Saus
Cristina Puig-Saus
RYRuby Yu
Ruby Yu
ESEric Shifrut
Eric Shifrut
JCJulia Carnevale
Julia Carnevale
AMAlex Marson
Alex Marson

20 August 2014 in JAMA
Verified
Journal Article
Open access
PDF file
AKAntonia Kwan
Antonia Kwan
RARoshini S. Abraham
Roshini S. Abraham
RCRobert J. Currier
Robert J. Currier
ABAmy Brower
Amy Brower
KAKaren Andruszewski
Karen Andruszewski
JPJennifer M. Puck
Jennifer M. Puck
The purpose of newborn screening is early detection of inborn conditions for which prompt treatments mitigate mortality or irreversible damage. The first heritable immune disorders to which newborn screening has been applied are those that together comprise severe combined immunodeficiency (SCID), caused by defects in any of a diverse group of gene products essential for development of adaptive immunity provided by T and B lymphocytes.1,2 A feature of all SCID is defective production of T cells. In most SCID, B cells are also defective, but even normal B cells cannot produce antibodies without T-cell help. Thus, infants with SCID are susceptible to life-threatening infections. Early detection and treatment optimize survival.3-5 Provided that SCID is diagnosed before infections become overwhelming, affected infants can be rescued with hematopoietic stem cell transplantation; gene therapy; or, for adenosine deaminase deficiency, enzyme replacement therapy.2,5-8

14 September 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
NRNeil Romberg
Neil Romberg
KMKhatoun Al Moussawi
Khatoun Al Moussawi
CNCarol Nelson-Williams
Carol Nelson-Williams
ASAmy L Stiegler
Amy L Stiegler
ELErin Loring
Erin Loring
RLRichard P Lifton
Richard P Lifton
Richard Lifton, Barbara Kazmierczak and colleagues report the identification of a new enterocolitic and autoinflammatory syndrome, which they find is caused by de novo gain-of-function mutations affecting the inflammasome protein NLRC4. Cells with mutant NLRC4 produce elevated levels of cleaved caspase-1, which leads to cell death by pyroptosis. Upon detection of pathogen-associated molecular patterns, innate immune receptors initiate inflammatory responses. These receptors include cytoplasmic NOD-like receptors (NLRs) whose stimulation recruits and proteolytically activates caspase-1 within the inflammasome, a multiprotein complex. Caspase-1 mediates the production of interleukin-1 family cytokines (IL1FCs), leading to fever and inflammatory cell death (pyroptosis)1,2. Mutations that constitutively activate these pathways underlie several autoinflammatory diseases with diverse clinical features3. We describe a family with a previously unreported syndrome featuring neonatal-onset enterocolitis, periodic fever, and fatal or near-fatal episodes of autoinflammation. We show that the disease is caused by a de novo gain-of-function mutation in NLRC4 encoding a p.Val341Ala substitution in the HD1 domain of the protein that cosegregates with disease. Mutant NLRC4 causes constitutive IL1FC production and macrophage cell death. Infected macrophages from affected individuals are polarized toward pyroptosis and exhibit abnormal staining for inflammasome components. These findings identify and describe the cause of a life-threatening but treatable autoinflammatory disease that underscores the divergent roles of the NLRC4 inflammasome.

26 January 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MOMichael J. Ombrello
Michael J. Ombrello
ERElaine F. Remmers
Elaine F. Remmers
GSGuangping Sun
Guangping Sun
AFAlexandra F. Freeman
Alexandra F. Freeman
SDShrimati Datta
Shrimati Datta
JMJoshua D. Milner
Joshua D. Milner
Mendelian analysis of disorders of immune regulation can provide insight into molecular pathways associated with host defense and immune tolerance. We identified three families with a dominantly inherited complex of cold-induced urticaria, antibody deficiency, and susceptibility to infection and autoimmunity. Immunophenotyping methods included flow cytometry, analysis of serum immunoglobulins and autoantibodies, lymphocyte stimulation, and enzymatic assays. Genetic studies included linkage analysis, targeted Sanger sequencing, and next-generation whole-genome sequencing. Cold urticaria occurred in all affected subjects. Other, variable manifestations included atopy, granulomatous rash, autoimmune thyroiditis, the presence of antinuclear antibodies, sinopulmonary infections, and common variable immunodeficiency. Levels of serum IgM and IgA and circulating natural killer cells and class-switched memory B cells were reduced. Linkage analysis showed a 7-Mb candidate interval on chromosome 16q in one family, overlapping by 3.5 Mb a disease-associated haplotype in a smaller family. This interval includes PLCG2, encoding phospholipase Cγ2 (PLCγ2), a signaling molecule expressed in B cells, natural killer cells, and mast cells. Sequencing of complementary DNA revealed heterozygous transcripts lacking exon 19 in two families and lacking exons 20 through 22 in a third family. Genomic sequencing identified three distinct in-frame deletions that cosegregated with disease. These deletions, located within a region encoding an autoinhibitory domain, result in protein products with constitutive phospholipase activity. PLCG2-expressing cells had diminished cellular signaling at 37°C but enhanced signaling at subphysiologic temperatures. Genomic deletions in PLCG2 cause gain of PLCγ2 function, leading to signaling abnormalities in multiple leukocyte subsets and a phenotype encompassing both excessive and deficient immune function. (Funded by the National Institutes of Health Intramural Research Programs and others.)

1 May 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
SCScott W. Canna
Scott W. Canna
CGCharlotte Girard-Guyonvarc’h
Charlotte Girard-Guyonvarc’h
LMLouise Malle
Louise Malle
AJAdriana de Jesus
Adriana de Jesus
NRNeil Romberg
Neil Romberg
EBEdward M. Behrens
Edward M. Behrens

19 June 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CMChi A Ma
Chi A Ma
JSJeffrey R Stinson
Jeffrey R Stinson
YZYuan Zhang
Yuan Zhang
JAJordan K Abbott
Jordan K Abbott
MWMichael A Weinreich
Michael A Weinreich
JMJoshua D Milner
Joshua D Milner
Erwin Gelfand, Andrew Snow, Joshua Milner and colleagues identify heterozygous CARD11 mutations associated with severe atopic disease in eight individuals from four families. They further show that the mutant CARD11 proteins exhibit both loss-of-function and dominant-interfering activity and that the cellular defects in patient T cells can be partially rescued by supplementing with glutamine. Few monogenic causes for severe manifestations of common allergic diseases have been identified. Through next-generation sequencing on a cohort of patients with severe atopic dermatitis with and without comorbid infections, we found eight individuals, from four families, with novel heterozygous mutations in CARD11, which encodes a scaffolding protein involved in lymphocyte receptor signaling. Disease improved over time in most patients. Transfection of mutant CARD11 expression constructs into T cell lines demonstrated both loss-of-function and dominant-interfering activity upon antigen receptor–induced activation of nuclear factor-κB and mammalian target of rapamycin complex 1 (mTORC1). Patient T cells had similar defects, as well as low production of the cytokine interferon-γ (IFN-γ). The mTORC1 and IFN-γ production defects were partially rescued by supplementation with glutamine, which requires CARD11 for import into T cells. Our findings indicate that a single hypomorphic mutation in CARD11 can cause potentially correctable cellular defects that lead to atopic dermatitis.